Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis

BACKGROUND: The clinical significance of tumor-specific genomic alterations in metastatic renal cell carcinoma (mRCC) is emerging, with several studies suggesting an association between PBRM1 mutations and response with immunotherapy (IO). We sought to determine genomic predictors of differential re...

Descripción completa

Detalles Bibliográficos
Autores principales: Dizman, Nazli, Lyou, Yung, Salgia, Nicholas, Bergerot, Paulo Gustavo, Hsu, JoAnn, Enriquez, Daniel, Izatt, Tyler, Trent, Jeffrey M, Byron, Sara, Pal, Sumanta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359179/
https://www.ncbi.nlm.nih.gov/pubmed/32661119
http://dx.doi.org/10.1136/jitc-2020-000953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359179/
https://www.ncbi.nlm.nih.gov/pubmed/32661119
http://dx.doi.org/10.1136/jitc-2020-000953

Ejemplares similares